Elevance Health reported first-quarter 2025 operating revenue of $48.8 billion, a 15% increase compared to the prior year quarter. This growth was driven by higher premium yields in Health Benefits, recent acquisitions, and membership growth in Medicare Advantage and Individual ACA plans.
Adjusted diluted earnings per share for the quarter was $11.97, an increase of 10.5% year-over-year, surpassing analyst expectations. The company reaffirmed its adjusted diluted EPS guidance for 2025 in the range of $34.15 to $34.85, indicating a stable outlook.
The Carelon segment's operating revenue surged by 38% to $16.7 billion, driven by acquisitions in home health and pharmacy services and the scaling of risk-based capabilities. The Board of Directors declared a second-quarter 2025 dividend of $1.71 per share, payable on June 25, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.